15289-s-bos

4 69 | Rebuttal AoVC in FH References 1. N.M. Rajamannan, F.J. Evans, E. Aikawa, et al.Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the national heart and lung and blood institute aortic stenosis working group. Executive summary: calcific aortic valve disease-2011 updateCirculation, 124 (2011), pp. 1783-1791 2. N.M. Rajamannan, M. Subramaniam, D. Rickard, et al.Human aortic valve calcification is associated with an osteoblast phenotypeCirculation, 107 (2003), pp. 2181-2184 3. G.-J.R. ten Kate, S. Bos, A. Dedic, et al.Increased aortic valve calcification in familial hypercholesterolemia: prevalence, extent, and associated risk factorsJ Am Coll Cardiol, 66 (2015), pp. 2687-2695 ArticlePDF (643KB) 4. N.M. RajamannanMechanisms of aortic valve calcification: the LDL-density-radius theory: a translation from cell signaling to physiologyAm J Physiol Heart Circ Physiol, 298 (2010), pp. H5-H15 5. N.M. RajamannanThe role of Lrp5/6 in cardiac valve disease: LDL-density-pressure theoryJ Cell Biochem, 112 (2011), pp. 2222-2229 6. N.M. Rajamannan, A.M. Greve, L.M. Moura, et al.SALTIRE-RAAVE: targeting calcific aortic valve disease LDL-density-radius theoryExpert Rev Cardiovasc Ther, 13 (2015), pp. 355-367 7. Bernoullid.HydrodynamicasivedeviribusetmotibusfluidorumcommentarriiStrasbourg:Argentoratum. St.31. 1738. 8. Y. Tintut, Z. Alfonso, T. Saini, et al.Multilineage potential of cells from the artery wallCirculation, 108 (2003), pp. 2505-2510 9. N.M. Rajamannan, W.D. Edwards, T.C. SpelsbergHypercholesterolemic aortic-valve diseaseN Engl J Med, 349 (2003), pp. 717-718 Dr. Rajamannan is the inventor on a patent for methods to slow progression of aortic valve disease; the patent is owned by the Mayo Clinic, with no royalty payments to the inventor.